You're not compounding, you are manufacturing. That's the line South Africa's top medicines regulator uses for pharmacies that turn out weight-loss jabs in bulk. It's Monday, October 26, and this is GLP-1 Daily. South Africa's fight with bulk compounders and the black market leads. After that, Belgium says no to paying for Mounjaro for obesity, and a new study looks at who actually started the Wegovy pill. Hit follow and you won't have to come looking for the next episode.
Linda Nordling, for the Bhekisisa Centre for Health Journalism, in Daily Maverick:
But some pharmacies produce large quantities without that evidence, Sahpra chief executive Boitumelo Semete-Makokotlela told Bhekisisa. This means “you’re not compounding, you are manufacturing”, which requires a good manufacturing practice licence that compounding pharmacies do not hold.
Some context. In South Africa, compounding is legal with a prescription, usually for a form that isn't sold as a registered medicine. Making stock in advance is allowed only when a pharmacy can show patients regularly need it. In June, the Gauteng High Court ordered a Tshwane pharmacy called iDexis to stop making semaglutide products after large quantities were confiscated there. The piece ran Friday and draws on an October 14 panel in Sandton with regulators, police, border and revenue officials. Sahpra says it has received about 600 complaints this financial year about illegitimate medicines sold through online portals, gyms and even hairdressers. Retatrutide, which isn't licensed anywhere, is sold openly there too. And the fix is slow. Revised guidelines for compounding pharmacies aren't expected until February or March 2027. Stavros Nicolaou, who chairs an industry umbrella group, calls that too late and asks why South Africa hasn't restricted compounding of these jabs like other countries. Australia has banned it. Weigh the speaker: Nicolaou represents the pharmaceutical industry, which has a stake here. On the reported U.S. death earlier this year after injections sold as retatrutide, the article notes the BMJ called the evidence less clear cut than media reports suggested. This adds a new country to the retatrutide market we followed all last week, through Friday's CBS lab tests. What struck me is the candor. Sahpra's chief admits regulators are on the back foot, and says part of the answer is registered options at different prices, including cheaper generics. Warnings rarely win against price. Regulators listed warning signs: blank or unusual packaging, no expiry date, no insert, a dented box. If you aren't sure where your medicine came from, ask your pharmacist or prescriber before your next dose.
NAVLIN Daily, in a brief dated Thursday:
Belgium’s Health Minister Frank Vandenbroucke decided against reimbursing Eli Lilly’s Mounjaro (tirzepatide) for obesity treatment, citing budget and medical concerns, stressing that obesity needs more than just medication—it requires support from dietitians, psychologists, and lifestyle changes
Wegovy already got the same answer in Belgium. Mounjaro stays reimbursed for type 2 diabetes under strict conditions, and since February 2026 patients need prior approval from a health insurance physician. The brief says that rule targets diabetes drugs being used for weight loss. The budget figures: Belgian spending on GLP-1 drugs like Mounjaro rose from 30 million euros in 2019 to 122 million in 2025. A month's supply runs from about 180 to 411 euros, depending on dose. The minister isn't wrong that dietitians and psychologists matter. But refusing to pay for the drug doesn't pay for the dietitian either. People who can afford four hundred euros a month keep getting it, and everyone else gets advice. That's the two-tier pattern British MPs described in the report we covered Friday. Last Wednesday we aired Belgium's medicines agency warning about off-label use. This is the payer side of the same country. It's a short brief, so we'll watch for the ministry's fuller reasoning.
Pearl Steinzor, writing in AJMC about a research letter in JAMA Network Open:
Overall, 53.0% of oral semaglutide initiators had no GLP-1 RA use in the prior 12 months. The most common prior exposures were injectable semaglutide (28.9% of all oral semaglutide initiators) and injectable tirzepatide (27.5%).
The setup: University of Pennsylvania researchers used Epic Cosmos health records covering nearly 48 million U.S. adults eligible for obesity drugs, from the pill's approval on December 22, 2025, to mid-March. About 149,000 started oral semaglutide, against 227,000 for injectable semaglutide and 356,000 for tirzepatide. Pill starts peaked in week ten, in early March, and briefly passed the injection. Tirzepatide led the whole time. Pill starters skewed a little older and more often female, and 13.4 percent were on Medicare, versus about 9 and 10 percent for the injectables. So roughly half were brand new, and the rest were mostly switching. The pill opened a door for some people. For others it's just a different way to take what they already had. The authors list the limits. The records don't show why a drug was prescribed, an order isn't proof anyone filled or took it, and online and direct-to-consumer prescriptions may be missed. It's descriptive and unadjusted. On October 14 we covered an Annals study counting more than 100,000 new pill prescriptions by month two. This one adds who those patients were. If you're weighing the pill against your shot, take that to your prescriber, along with what your plan covers for each.
Listening from outside the U.S.? We'd like to hear how coverage works where you are, whether it's a reimbursement rule, a pharmacy shortage or a price you've been quoted. Write to glp1daily at lantern podcasts dot com.
The Daily Maverick report, the NAVLIN brief and the AJMC write-up are linked in the show notes. We're back tomorrow, Tuesday. GLP-1 Daily is part of the Lantern Podcasts family.